INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
Sponsor: Duke University
This EARLY_PHASE1 trial investigates Metastatic Castration-resistant Prostate Cancer (mCRPC) and Metastatic Renal Cell Carcinoma and is currently completed. Duke University leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
May 2022 — Jul 2024 [monthly]
Completed EARLY_PHASE1
Status: Recruiting → Completed
-
Sep 2021 — May 2022 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting EARLY_PHASE1
▶ Show 10 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
Status: Suspended → Recruiting
-
May 2020 — Sep 2020 [monthly]
Suspended EARLY_PHASE1
Status: Recruiting → Suspended
-
Nov 2019 — May 2020 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2019 — Nov 2019 [monthly]
Recruiting EARLY_PHASE1
-
May 2019 — Sep 2019 [monthly]
Recruiting EARLY_PHASE1
-
Mar 2019 — May 2019 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2018 — Mar 2019 [monthly]
Recruiting EARLY_PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Recruiting EARLY_PHASE1
-
Aug 2017 — Oct 2017 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2017 — Aug 2017 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Duke University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Durham, United States